Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data

NCT05577728 · Completed

Last updated 2026-05-28

This clinical trial aims to predict long-term blood sugar control in people with type 2 diabetes using healthcare claims data.

Status Completed The study has finished.

Type Observational

Participants 2,316 people

Who can join Ages 18+ · all sexes

Timeline Started 2021-07 · est. completion 2022-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05577728 ↗

Description as written by the study sponsor.

Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.

Treatments tested

New use of semaglutide injection Drug

New use of semaglutide injection dispensing claim is used as the exposure.
New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) Drug

New initiation of "standard of care" (SGL2i, 2nd generation SU, DPP-4i and GLP-1 RA except for semaglutide inj or oral) dispensing claim is used as the reference.

Main thing measured	Long-term glycemic control defined as proportion of patients who will achieve an HbA1c of less than 7.0% (53.0 mmol/mol)
Sponsor	Brigham and Women's Hospital
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05577728 ↗